Clinically Significant EBV Infection in Allogeneic Stem Cell Transplanted Children Receiving Letermovir as Primary CMV Prophylaxis. (PubMed, Transpl Infect Dis) - Apr 21, 2025 - "Our study confirms letermovir's effectiveness against CMV. Yet, it also reports a high incidence of EBV reactivation and significant EBV infection, as well as a reduced GvHD prevalence in children receiving the drug. Our single-center, retrospective analysis has major limitations but raises a concern. Our findings require further validation in larger, multicenter, prospective studies."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Transplantation
|
|
Aikaterini Kaisari; Anna Komitopoulou; Anna Paisiou; Christina Oikonomopoulou; Eleni-Dikaia Ioannidou; Evgenios Goussetis; Georgia Stavroulaki; Ioannis Grafakos; Marina Letsiou; Michalis Kastamoulas; Sofia Hante
|